대사체학 시장 보고서 : 제품별, 적응증별, 용도별, 지역별(2025-2033년)

The global metabolomics market size reached USD 3.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.0 Billion by 2033, exhibiting a growth rate (CAGR) of 9.28% during 2025-2033. The growing demand for personalized medicine, rising prevalence of chronic diseases, expanding pharmaceutical and biotechnology research, and the need for advanced biomarker and drug discovery solutions are some of the major factors propelling the market.

Metabolomics is a cutting-edge field in the realm of life sciences that focuses on the comprehensive study of small molecules called metabolites within biological systems. These metabolites include substances such as sugars, amino acids, lipids, and other cellular compounds, and they play crucial roles in various biological processes. Metabolomics employ advanced analytical techniques, such as mass spectrometry and nuclear magnetic resonance spectroscopy, to identify and quantify these metabolites. By doing so, it offers insights into an organism's metabolic state, providing valuable information about health, disease, drug responses, and environmental influences.

The global metabolomics market is experiencing robust growth, primarily driven by the growing recognition of the pivotal role that this compound plays in personalized medicine and healthcare. In line with this, metabolomics provides a powerful tool for understanding an individual's unique metabolic profile, enabling more precise diagnosis, treatment selection, and tailored healthcare plans, thereby strengthening the market growth. Moreover, the increasing prevalence of chronic diseases and the need for early disease detection and prevention are boosting demand for metabolomics technologies, creating a positive outlook for market expansion. In addition to this, the widespread adoption of these technologies to identify metabolic biomarkers associated with diseases, facilitating early intervention and monitoring, is contributing to the market's growth. Furthermore, the expansion of pharmaceutical and biotechnology research, coupled with the drive for drug discovery and development, is fueling demand for metabolomics to elucidate drug mechanisms, predict drug efficacy, and assess safety.

Metabolomics Market Trends/Drivers:

Advancements in personalized medicine

One of the foremost drivers of the metabolomics market is the increasing importance of personalized medicine. Healthcare is moving away from a one-size-fits-all approach, and metabolomics plays a pivotal role in tailoring treatments to individual patients. This shift is largely due to the recognition that genetic variations alone do not provide a complete understanding of an individual's health. Metabolomics complements genomics by capturing dynamic changes in an individual's metabolic profile, reflecting their unique response to diseases, drugs, and environmental factors. As a result, metabolomics enables healthcare providers to make more precise diagnoses, select personalized treatment options, and monitor therapeutic responses. For example, in cancer treatment, metabolomics can identify specific metabolic pathways that are dysregulated in a patient's tumor, helping oncologists choose the most effective therapies.

Rising prevalence of chronic diseases

The escalating global burden of chronic diseases including diabetes, cardiovascular disorders, and obesity is another significant driver of the metabolomics market. Metabolomics provides a powerful tool for early disease detection, risk assessment, and monitoring. By analyzing metabolic biomarkers, researchers and clinicians can identify subtle changes in an individual's metabolic profile that may precede the clinical manifestation of a disease. This early warning system is crucial for implementing preventive measures, initiating treatments at the earliest stages of disease development, and tracking disease progression. Additionally, as lifestyle-related factors contribute to the rise in chronic diseases, metabolomics can shed light on how dietary choices, physical activity, and environmental exposures impact an individual's metabolic health.

Pharmaceutical and biotechnology research

The pharmaceutical and biotechnology sectors are increasingly relying on metabolomics to enhance drug discovery and development processes. Metabolomics offers insights into drug mechanisms, efficacy, and safety, thereby accelerating the drug development pipeline. Researchers use metabolomics to identify and validate drug targets, assess the metabolic effects of potential drug candidates, and predict their pharmacokinetics and toxicity. This information helps streamline the drug development process, reduce costly late-stage failures, and improve the chances of bringing innovative therapies to market. Moreover, metabolomics is crucial for understanding drug interactions, optimizing dosing regimens, and monitoring patient responses during clinical trials, contributing to the overall efficiency and success of drug development efforts.

Metabolomics Industry Segmentation:

Breakup by Product:

Metabolomics Instruments

Metabolomics Bioinformatics Tools and Services

Metabolomics bioinformatics tools and services dominate the market

The demand for metabolomics bioinformatic tools and services is mainly propelled by the complexity and volume of data generated in metabolomics research. Metabolomics experiments produce vast datasets with intricate molecular information, making data analysis and interpretation a significant challenge. Besides this, metabolomics bioinformatic tools and services are essential for processing, managing, and extracting meaningful insights from this wealth of data. Furthermore, the integration of multi-omics data, including genomics, proteomics, and metabolomics, is becoming increasingly crucial to gain a holistic understanding of biological systems. To harness the full potential of metabolomics data, researchers require sophisticated software solutions and expert services that can handle data preprocessing, statistical analysis, pathway mapping, and biomarker identification. As metabolomics continues to expand its applications in diverse fields, the demand for bioinformatic tools and services is set to rise, enabling researchers to unlock the valuable information hidden within their datasets.

Breakup by Indication:

Cancer

Cardiovascular Disorders

Neurological Disorders

Inborn Errors of Metabolism

Others

Cancer holds the largest share in the market

The urgent need for more precise and early detection methods, as well as personalized treatment strategies in cancer research and diagnostics is strengthening the demand for metabolomics. They offer a unique advantage in cancer studies by providing a real-time snapshot of an individual's metabolic profile, allowing for the identification of specific metabolic alterations associated with different types and stages of cancer. These metabolic signatures can serve as potential biomarkers for early cancer detection, enabling clinicians to detect malignancies at a more treatable stage. Furthermore, as cancer treatment often leads to metabolic changes and varying responses in patients, metabolomics can assist in tailoring therapeutic approaches by monitoring how a patient's metabolism reacts to specific cancer treatments. This personalized approach has the potential to enhance treatment outcomes and minimize adverse effects, driving the demand for metabolomics applications in the field of oncology.

Breakup by Application:

Biomarker and Drug Discovery

Toxicology

Nutrigenomics

Personalized Medicine

Others

Biomarker and drug discovery dominates the market

The burgeoning demand for metabolomics in biomarker and drug discovery applications is driven by its unparalleled ability to unveil novel biomarkers and therapeutic targets. Metabolomics allows researchers to delve deep into an organism's biochemical landscape, identifying subtle metabolic changes associated with diseases and drug responses that may go unnoticed by other omics techniques. This capability is invaluable in biomarker discovery, where metabolomics can pinpoint specific metabolites indicative of disease presence, progression, or treatment efficacy. Additionally, in drug discovery, metabolomics plays a pivotal role in elucidating drug mechanisms and assessing potential drug candidates' safety profiles by uncovering their metabolic impact. By providing a comprehensive view of the intricate interactions within biological systems, metabolomics accelerates the identification of promising drug targets, expedites the development of new therapies, and minimizes the risk of late-stage drug failures, thereby fueling the demand for metabolomics in these critical areas of research.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest metabolomics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a thriving biopharmaceutical and healthcare industry, characterized by substantial investments in research and development (R&D). This robust ecosystem fuels the demand for metabolomics technologies in drug discovery and personalized medicine applications, as pharmaceutical companies seek innovative solutions to expedite drug development and enhance patient care. Concurrent with this, the region's healthcare infrastructure places a strong emphasis on precision medicine, with government initiatives and healthcare institutions increasingly recognizing the potential of metabolomics for tailoring treatments and improving patient outcomes. Furthermore, collaborations between academic research institutions and industry players in North America have paved the way for cutting-edge metabolomics research, further propelling the market's growth. These factors, combined with a favorable regulatory environment, position North America as a key hub for metabolomics innovation and adoption, driving the market forward.

Competitive Landscape:

The competitive landscape of the global metabolomics market is dynamic and characterized by intense competition among both established players and emerging companies. Leading companies dominate the market with their comprehensive portfolios of metabolomics instruments, software, and services. These industry giants focus on continuous innovation, strategic partnerships, and acquisitions to expand their market presence and offer integrated solutions to customers. Additionally, academic institutions and research organizations contribute significantly to the market by developing cutting-edge metabolomics technologies and methodologies and fostering collaborations with industry stakeholders. Emerging startups, specializing in niche metabolomics applications, are also gaining traction by introducing innovative tools and services, enhancing competition and driving market growth. Furthermore, the market's global nature makes it highly competitive on a regional basis, with regional players catering to specific geographical preferences and regulations.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Agilent Technologies Inc.

Biocrates Life Sciences AG

Bio-Rad Laboratories Inc.

Bruker Corporation

Danaher Corporation

Human Metabolome Technologies Inc.

Metabolon Inc.

Shimadzu Corporation

Thermo Fisher Scientific Inc.

Waters Corporation

Key Questions Answered in This Report:

• How has the global metabolomics market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global metabolomics market?
• What is the impact of each driver, restraint, and opportunity on the global metabolomics market?
• What are the key regional markets?
• Which countries represent the most attractive metabolomics market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the metabolomics market?
• What is the breakup of the market based on the indication?
• Which is the most attractive indication in the metabolomics market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the metabolomics market?
• What is the competitive structure of the global metabolomics market?
• Who are the key players/companies in the global metabolomics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Metabolomics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Metabolomics Instruments
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Metabolomics Bioinformatics Tools and Services
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Indication

• 7.1 Cancer
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Cardiovascular Disorders
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Neurological Disorders
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Inborn Errors of Metabolism
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Application

• 8.1 Biomarker and Drug Discovery
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Toxicology
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Nutrigenomics
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Personalized Medicine
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Agilent Technologies Inc.
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Biocrates Life Sciences AG
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 Bio-Rad Laboratories Inc.
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Bruker Corporation
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
  • 13.3.5 Danaher Corporation
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 Human Metabolome Technologies Inc.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
  • 13.3.7 Metabolon Inc.
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
  • 13.3.8 Shimadzu Corporation
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Thermo Fisher Scientific Inc.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Waters Corporation
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis